Evidence map›Paper›PMID 40273086›Full record

ArticlePloS one2025

Inhibitive effect of Urginea epigea methanolic extract and silver/zinc oxide nanoparticles on Aspergillus and aflatoxin production.

Martha Cebile Jobe, Mulunda Mwanza

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Martha Cebile JobeDepartment of Animal Health, North-West University, Mahikeng Campus, Mmabatho, Mahikeng, South Africa.ORCID 0000-0002-1703-3437
Mulunda MwanzaDepartment of Animal Health, North-West University, Mahikeng Campus, Mmabatho, Mahikeng, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Food crops contaminated with Aspergillus flavus due to aflatoxins can be hazardous for both humans and animals, hence endeavours are being explored to find natural antifungals to combat the contamination and mycotoxin issue. The current study used the agar dilution method to assess the effect of Urginea epigea methanolic extract and biosynthesized silver-zinc oxide nanoparticles on the toxigenic strain of Aspergillus. In the experiment, an aflatoxin-producing strain was used, and potato dextrose agar was diluted with methanolic extract from U. epigea and silver/zinc oxide nanoparticles at concentrations of 0, 6.5, 12, 25, and 50 mg/mL, respectively. Mycelia growth diameters were measured to test inhibitory activity. A significant decrease in fungal growth was observed at different concentrations (P < 0,05) when compared to the control. At 50 mg/mL, the extract of U. epigea significantly reduced the growth of A. flavus by 100%. PCR data shows that the expression of aflD and aflR was significantly downregulated (P < 0.005) by the treatments, with U. epigea having a 50fold decrease when compared to Ag/ZnO nanoparticles. Compared to the controls, Ag/ZnO nanoparticles down-regulated the expression of aflD and aflR in A. flavus by more than 30-fold. However, there was less expression by nanoparticles, as evidenced by the sequence alignment. A. flavus growth and aflatoxin B1 production were both considerably suppressed by U. epigea methanolic extract, through the presence of phytochemicals thus has the potential to be employed as an alternative antifungal agent to control aflatoxigenic fungus. The study recommends investigating and extracting the active compound present in the U. epigea bulb.

Indexed as

AflatoxinsAntifungal AgentsAspergillusAspergillus flavusMetal NanoparticlesPlant ExtractsSilverZinc OxideMethanolAflatoxinsAntifungal AgentsMethanolPlant ExtractsSilverZinc Oxide

Identifiers

PMID40273086
PMCPMC12021180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.